Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis
暂无分享,去创建一个
D. Goodkin | D E Goodkin | D C Mohr | L P Dick | D Russo | A C Boudewyn | L Masuoka | J Eckhardt | L Bedell | D. Mohr | A. Boudewyn | L. P. Dick | L. Masuoka | David Russo | Jannelle Eckhardt | Lisa Bedell
[1] D. Mohr,et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. , 1997, Archives of neurology.
[2] D. Mohr,et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.
[3] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[4] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[5] D. Mohr. Negative Outcome in Psychotherapy: A Critical Review , 1995 .
[6] M. Dimatteo,et al. Enhancing Medication Adherence Through Communication and Informed Collaborative Choice , 1994 .
[7] Judith A. Hall,et al. Task Versus Socioemotional Behaviors in Physicians , 1987, Medical care.
[8] J. Probstfield,et al. Successful program for recovery of dropouts to a clinical trial. , 1986, The American journal of medicine.
[9] W. Bahlman. Innovative combination clinical trial designs/patient compliance: a community perspective. , 1996, Antiviral research.